The University of Chicago Comprehensive Cancer Center (UCCCC) Transgenic Mouse/Embryonic Stem Cell Facility provides comprehensive genetic engineering services to alter the genome of the laboratory mouse. The UCCCC has many invesfigators who use mouse models as their primary tool of analysis, as well as a multitude of addifional investigators who require the occasional mouse model in their studies of the causes and treatment of cancer. The generation and maintenance of transgenic animals through the microinjection of single-celled mouse embryos, and the generation of genetically modified mice through the use of ES cells require specialized technical personnel. Furthermore, such efforts necessitate the acquisition of an array of devoted equipment. Thus, the availability of a shared resource greatly reduces research costs for the individual investigators of the UCCCC. The existence of this Facility also greatly increases the accessibility of genetic engineering technology to investigators with limited related experience. The UCCCC Transgenic Mouse/Embryonic Stem Cell Facility was established in 1991, and has been tremendously productive and successful;the range of services provided has expanded considerably since it's founding. Services provided by the Transgenic Mouse/Embryonic Stem Cell Facility include: 1) transgenic mouse production from founder through F1 Stage;2) ES cell technology mouse production;3) ES cell gene targeting and culturing;4) embryo rederivation;5) mouse embryonic feeder (MEF) cell production;6) Timed pregnancies of various strains and lines of mice;7);various breeding services and GEM model line maintenance;8) DNA preparation from ES cell lines;and 9) design and construction of transgenic or ES cell targeting vectors. In addition to the technical services, the Facility also offers assistance with the design of studies that require mouse molecular genetics, as well as advice and instruction on mouse handling and breeding. In providing these comprehensive services, the UCCCC Transgenic Mouse/Embryonic Stem Cell Facility has generated mouse models that have led to advances in our understanding of cancer, including cancers of the breast, skin, colon, brain and prostate.
This Facility generates mouse models of human disease to facilitate UCCCC member's research into the molecular mechanisms of cancer biology. As such, it is an integral part of the scienfific success of UCCCC members.
|Feng, Christine H; Gerry, Emily; Chmura, Steven J et al. (2015) An image-guided study of setup reproducibility of postmastectomy breast cancer patients treated with inverse-planned intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys 91:58-64|
|Ming, Mei; Zhao, Baozhong; Shea, Christopher R et al. (2015) Loss of sirtuin 1 (SIRT1) disrupts skin barrier integrity and sensitizes mice to epicutaneous allergen challenge. J Allergy Clin Immunol 135:936-45.e4|
|Ming, Mei; Zhao, Baozhong; Qiang, Lei et al. (2015) Effect of immunosuppressants tacrolimus and mycophenolate mofetil on the keratinocyte UVB response. Photochem Photobiol 91:242-7|
|Shah, Palak; He, Yu-Ying (2015) Molecular regulation of UV-induced DNA repair. Photochem Photobiol 91:254-64|
|Ming, Mei; Han, Weinong; Zhao, Baozhong et al. (2014) SIRT6 promotes COX-2 expression and acts as an oncogene in skin cancer. Cancer Res 74:5925-33|
|Ramírez, Jacqueline; Kim, Tae Won; Liu, Wanqing et al. (2014) A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469. Pharmacogenet Genomics 24:129-32|
|Rudra, Sonali; Al-Hallaq, Hania A; Feng, Christine et al. (2014) Effect of RTOG breast/chest wall guidelines on dose-volume histogram parameters. J Appl Clin Med Phys 15:4547|
|Weng, Liming; Ziliak, Dana; Lacroix, Bonnie et al. (2014) Integrative "omic" analysis for tamoxifen sensitivity through cell based models. PLoS One 9:e93420|
|Stumpf, Melanie; Zhou, Xuyu; Chikuma, Shunsuke et al. (2014) Tyrosine 201 of the cytoplasmic tail of CTLA-4 critically affects T regulatory cell suppressive function. Eur J Immunol 44:1737-46|
|Geeleher, Paul; Cox, Nancy J; Huang, R Stephanie (2014) Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines. Genome Biol 15:R47|
Showing the most recent 10 out of 354 publications